Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Event-Driven, Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy, Safety, Immunogenicity, Lot-to-Lot Consistency of BBV152, a Whole-Virion Inactivated SARS-CoV-2 Vaccine in Adults≥18 Yrs of Age

NCT04641481 is registered in ClinicalTrials.gov with Bharat Biotech International Limited as lead sponsor.

NCT NCT04641481
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04641481 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Event-Driven, Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy, Safety, Immunogenicity, Lot-to-Lot Consistency of BBV152, a Whole-Virion Inactivated SARS-CoV-2 Vaccine in Adults≥18 Yrs of Age
Lead sponsor
Bharat Biotech International Limited
Phase
Phase 3
Overall status
Unknown status
Start date
November 16, 2020
Completion date
December 31, 2022
Enrollment
25,800 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid19, sars-cov infection